Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: Response to albuterol, isoproterenol, and placebo aerosols,☆☆

https://doi.org/10.1016/0091-6749(77)90048-3Get rights and content

Abstract

Albuterol aerosol was an effective bronchodilator as reflected by indices of pulmonary function obtained from spirometry and flow volume curves. Compared with isoproterenol, there were minimal side effects even at the highest doses, and bronchodilatation lasted significantly longer. In addition albuterol was successfully used by a patient with idiopathic hypertrophic subaortic stenosis who was unable to tolerate isoproterenol, as well as by some patients with idiosyncratic responses to isoproterenol. A few patients appeared to derive little benefit from either albuterol or isoproterenol.

References (18)

There are more references available in the full text version of this article.

Cited by (20)

  • Cardiovascular risks associated with β-agonist therapy [3]

    2005, Chest
    Citation Excerpt :

    The study by Pearlman et al18 included three groups and hence 67 patients rather than 46 patients in the β-agonist treatment. The studies by Spector and Garza Gomez17 and Anderson et al19 included two β-agonist treatments rather than one, and, hence, the study groups should have been twice the number reported. The study by Nathan et al20 included only the data from the salmeterol group (4 of 369 patients), not the data for the albuterol group, and, most importantly, it improperly stated that the placebo rate was 0 of 187 patients, although this was not the information presented in the article.

  • Cardiovascular effects of β-agonists in patients with asthma and COPD: A meta-analysis

    2004, Chest
    Citation Excerpt :

    There were a total of 232 participants, with a mean age of 56.6 years. Of the longer duration trials, 14 were of asthma and 6 were of COPD.36–55 There was a total of 6,623 participants with a mean age of 52.2 years in these trials, which ranged in duration from 3 days to 1 year with a mean trial duration of 4.7 months.

  • Comparison of inhaled albuterol powder and aerosol in asthma

    1987, The Journal of Allergy and Clinical Immunology
View all citing articles on Scopus

Supported in part by Allergic Disease Center Grant No. AI-10398.

☆☆

Presented in part at the American Academy of Allergy Thirty-second Annual Meeting, March 8 to 10, 1976, San Juan, Puerto Rico.

View full text